SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CUBIST PHARMACEUTICALS (CBST)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who wrote (246)4/8/2011 1:46:35 AM
From: tuck   of 252
 
"Flagyl is first line right now."

In most cases, yes. Flagyl IS cheaper. But if the colitis is severe, some docs will go straight to vanco because it achieves a higher concentration in the gut than Flagyl. Whichever drug is used, about 20% of patients relapse, so then either vanco or Dificid could be used. Your point is well taken though; first line vanco patients are uncommon, and second line would most likely be vanco versus Dificid. But for those who relapse more than once, Dificid might be nice to have. I must say, it does not seem like much of a market.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News